{"id":"https://openalex.org/W4243475288","doi":"https://doi.org/10.1182/bloodadvances.2018020198","title":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","display_name":"No free rides: management of toxicities of novel immunotherapies in ALL, including financial","publication_year":2018,"publication_date":"2018-11-27","ids":{"openalex":"https://openalex.org/W4243475288","doi":"https://doi.org/10.1182/bloodadvances.2018020198","pmid":"https://pubmed.ncbi.nlm.nih.gov/30482769","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6258912"},"language":"en","primary_location":{"id":"doi:10.1182/bloodadvances.2018020198","doi":"https://doi.org/10.1182/bloodadvances.2018020198","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2018020198","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1182/bloodadvances.2018020198","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051833337","display_name":"Tania Jain","orcid":"https://orcid.org/0000-0001-6854-773X","observed_orcids":["https://orcid.org/0000-0001-6854-773X"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tania Jain","raw_affiliation_strings":["Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY; and","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085360755","display_name":"Mark Robert Litzow","orcid":"https://orcid.org/0000-0002-9816-6302","observed_orcids":["https://orcid.org/0000-0002-9816-6302"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark R. Litzow","raw_affiliation_strings":["Division of Hematology and Bone Marrow Transplant, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Bone Marrow Transplant, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":1.2555,"has_fulltext":false,"cited_by_count":58,"citation_normalized_percentile":{"value":0.75739491,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"2","issue":"22","first_page":"3393","last_page":"3403"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.8389000296592712,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.8389000296592712,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.15410000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/relapsed-refractory-leukemia","display_name":"relapsed/refractory leukemia","score":0.8840000033378601},{"id":"https://openalex.org/keywords/immunotherapy-toxicity","display_name":"immunotherapy toxicity","score":0.7870000004768372},{"id":"https://openalex.org/keywords/inotuzumab","display_name":"inotuzumab","score":0.9449999928474426},{"id":"https://openalex.org/keywords/hepatic-veno-occlusive-disease","display_name":"veno-occlusive disease","score":0.9190000295639038},{"id":"https://openalex.org/keywords/blinatumomab","display_name":"blinatumomab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.9879999756813049},{"id":"https://openalex.org/keywords/neurotoxicity","display_name":"neurotoxicity","score":0.9710000157356262},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.7829999923706055},{"id":"https://openalex.org/keywords/tocilizumab","display_name":"tocilizumab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.7879999876022339},{"id":"https://openalex.org/keywords/financial-toxicity","display_name":"financial toxicity","score":0.675000011920929},{"id":"https://openalex.org/keywords/cd22","display_name":"CD22","score":0.7480000257492065},{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.9729999899864197},{"id":"https://openalex.org/keywords/il-6-receptor-inhibition","display_name":"IL-6 receptor inhibition","score":0.765999972820282},{"id":"https://openalex.org/keywords/corticosteroids","display_name":"corticosteroids","score":0.9160000085830688}],"concepts":[{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.8519166707992554},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.8130300045013428},{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.7827805280685425},{"id":"https://openalex.org/C2778020697","wikidata":"https://www.wikidata.org/wiki/Q410189","display_name":"Blinatumomab","level":4,"score":0.7732272148132324},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7641611099243164},{"id":"https://openalex.org/C2779491297","wikidata":"https://www.wikidata.org/wiki/Q3338704","display_name":"Neurotoxicity","level":3,"score":0.5995556712150574},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5699540972709656},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3628455102443695},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.34621095657348633},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3231372833251953},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2701771855354309},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.24483722448349},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.2319793403148651},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2078879475593567},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.09354877471923828}],"mesh":[{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006504","descriptor_name":"Hepatic Veno-Occlusive Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006504","descriptor_name":"Hepatic Veno-Occlusive Disease","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D006504","descriptor_name":"Hepatic Veno-Occlusive Disease","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011089","descriptor_name":"Polydeoxyribonucleotides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016219","descriptor_name":"Immunotherapy, Adoptive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D020258","descriptor_name":"Neurotoxicity Syndromes","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1182/bloodadvances.2018020198","doi":"https://doi.org/10.1182/bloodadvances.2018020198","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2018020198","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5240254","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6258912","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6258912","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6258912","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Adv","raw_type":"Text"},{"id":"pmid:30482769","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30482769","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood advances","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1182/bloodadvances.2018020198","doi":"https://doi.org/10.1182/bloodadvances.2018020198","is_oa":true,"landing_page_url":"https://doi.org/10.1182/bloodadvances.2018020198","pdf_url":null,"source":{"id":"https://openalex.org/S2764683450","display_name":"Blood Advances","issn_l":"2473-9529","issn":["2473-9529","2473-9537"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","oarl","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G9000856728","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA008748","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":62,"referenced_works":["https://openalex.org/W1488000644","https://openalex.org/W1558914793","https://openalex.org/W1943300686","https://openalex.org/W1966771497","https://openalex.org/W1967512987","https://openalex.org/W1972172571","https://openalex.org/W1977380325","https://openalex.org/W1987935161","https://openalex.org/W1988623079","https://openalex.org/W1993783426","https://openalex.org/W1996815863","https://openalex.org/W2015956932","https://openalex.org/W2038139667","https://openalex.org/W2043873747","https://openalex.org/W2055482234","https://openalex.org/W2058056848","https://openalex.org/W2064322221","https://openalex.org/W2066508515","https://openalex.org/W2076106584","https://openalex.org/W2076560655","https://openalex.org/W2082189475","https://openalex.org/W2082708772","https://openalex.org/W2083001039","https://openalex.org/W2095124784","https://openalex.org/W2099570622","https://openalex.org/W2105400883","https://openalex.org/W2107925822","https://openalex.org/W2113426218","https://openalex.org/W2118241155","https://openalex.org/W2118796952","https://openalex.org/W2127742735","https://openalex.org/W2128272164","https://openalex.org/W2129702476","https://openalex.org/W2145985838","https://openalex.org/W2151348405","https://openalex.org/W2151475548","https://openalex.org/W2295805773","https://openalex.org/W2340435799","https://openalex.org/W2342423058","https://openalex.org/W2361098417","https://openalex.org/W2396687607","https://openalex.org/W2419639370","https://openalex.org/W2475083347","https://openalex.org/W2591709377","https://openalex.org/W2599899418","https://openalex.org/W2717189176","https://openalex.org/W2725721905","https://openalex.org/W2730231599","https://openalex.org/W2754562068","https://openalex.org/W2756071038","https://openalex.org/W2763751953","https://openalex.org/W2782994300","https://openalex.org/W2787301955","https://openalex.org/W2787621143","https://openalex.org/W2788008397","https://openalex.org/W2790768260","https://openalex.org/W2792588868","https://openalex.org/W2793787928","https://openalex.org/W2803430447","https://openalex.org/W2804159084","https://openalex.org/W2808092337","https://openalex.org/W2891446231"],"related_works":["https://openalex.org/W3001143067","https://openalex.org/W3095822969","https://openalex.org/W2557368153","https://openalex.org/W2949232578","https://openalex.org/W3011152171","https://openalex.org/W4200320635","https://openalex.org/W2913985417","https://openalex.org/W4389081787","https://openalex.org/W4323653039","https://openalex.org/W4390615212"],"abstract_inverted_index":{"Therapeutic":[0],"options":[1],"for":[2,172],"acute":[3],"lymphoblastic":[4],"leukemia,":[5],"especially":[6],"in":[7,14,80,196],"the":[8,21,34,39,62,146,170,187],"relapsed/refractory":[9],"setting,":[10],"have":[11],"expanded":[12],"significantly":[13],"recent":[15],"times.":[16],"However,":[17],"this":[18,152],"comes":[19],"at":[20],"cost":[22],"of":[23,33,61,82,105,143,148,151,192,203,214],"toxicities:":[24],"medical":[25],"as":[26,28],"well":[27],"financial.":[29],"We":[30],"highlight":[31],"some":[32],"unique":[35],"toxicities":[36,63,150],"associated":[37,85,96],"with":[38,65,86,97,113,124],"novel":[40],"agents":[41],"to":[42,48,51,56,145,161,217],"apprise":[43],"our":[44],"readers":[45],"about":[46],"what":[47],"expect,":[49],"how":[50,55],"recognize":[52],"them,":[53],"and":[54,102,110,116,121,184,208],"manage":[57],"these":[58,177,193,204],"toxicities.":[59],"One":[60],"seen":[64],"inotuzumab,":[66],"a":[67,90,141,180],"CD22":[68],"antibody":[69,92],"drug":[70],"conjugate,":[71],"is":[72,95,159,206],"sinusoidal":[73],"obstruction":[74],"syndrome,":[75],"which":[76,106],"can":[77],"be":[78,136,218],"fatal":[79],">80%":[81],"patients":[83],"if":[84],"multiorgan":[87],"failure.":[88],"Blinatumomab,":[89],"monoclonal":[91],"targeting":[93],"CD19,":[94],"cytokine":[98],"release":[99],"syndrome":[100],"(CRS)":[101],"neurotoxicity,":[103],"both":[104],"require":[107],"prompt":[108],"recognition":[109],"management":[111,147],"primarily":[112],"corticosteroids.":[114],"CRS":[115,164],"neurotoxicity":[117,173],"are":[118],"more":[119,122],"common":[120],"severe":[123,163],"chimeric":[125],"antigen":[126],"receptor":[127,157],"T-cell":[128],"therapy":[129],"(CAR-T).":[130],"The":[131],"fact":[132],"that":[133,198,209],"CAR-T":[134],"cannot":[135],"discontinued":[137],"on":[138,190,201,212],"demand":[139],"adds":[140],"layer":[142],"complexity":[144],"related":[149],"therapy.":[153],"Tocilizumab,":[154],"an":[155],"interleukin-6":[156],"blocker,":[158],"used":[160],"treat":[162],"from":[165],"CAR-T,":[166],"whereas":[167],"corticosteroids":[168],"remain":[169,216],"mainstay":[171],"management.":[174],"Although":[175],"effective,":[176],"drugs":[178],"carry":[179],"high":[181],"price":[182],"tag,":[183],"we":[185],"review":[186],"available":[188],"data":[189,211],"cost-effectiveness":[191],"agents,":[194],"keeping":[195],"mind":[197],"median":[199],"follow-up":[200],"most":[202],"studies":[205],"limited":[207],"long-term":[210],"durability":[213],"response":[215],"seen.":[219]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":18},{"year":2019,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-12T00:00:00"}